ReviewDrugs2001
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
Review in Drugs, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06767774 (Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus in Prediabetic Patients With Atherosclerotic Cardiovascular Disease), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus in Prediabetic Patients With Atherosclerotic Cardiovascular Disease
Who cites it
26 citing papers in PubMed, 109 citations in OpenAlex.
- Cholesterol in Mitochondrial Diseases-Friend or Foe?International journal of molecular sciences · 2026Review
- Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4/DPYSL2A axis.FEBS open bio · 2025Article
- The Quantum Paradox in Pharmaceutical Science: Understanding Without Comprehending-A Centennial Reflection.International journal of molecular sciences · 2025Review
- The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells.Scientific reports · 2023Article
- Review
- Microrchidia CW-Type Zinc Finger 2, a Chromatin Modifier in a Spectrum of Peripheral Neuropathies.Frontiers in cellular neuroscience · 2022Review
- PEG3 controls lipogenesis through ACLY.PloS one · 2021Article
- Novel approaches in anaplastic thyroid cancer therapy.The oncologist · 2014Review
- HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Cytosolic functions of MORC2 in lipogenesis and adipogenesis.Biochimica et biophysica acta · 2014Article
- Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information.BMJ open · 2013Article
- Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory.PloS one · 2013Article
- Dysregulation of the mevalonate pathway promotes transformation.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2008Review
- Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-lowering agents.Drug safety · 2007Review
- Atorvastatin: a safety and tolerability profile.Drugs · 2007 · on this mapReview
- Effects of atorvastatin on higher functions.European journal of clinical pharmacology · 2006Article
- [Statins for treatment of CNS diseases. Status report from research and clinical practice].Der Nervenarzt · 2005Review
- Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.CNS drugs · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercholesterolaemia is a chronic condition that often requires life-long treatment, making the safety of lipid-lowering drugs a critical issue. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ('statins') are commonly used as the pharmacotherapeutic treatment of choice for patients with hypercholesterolaemia. These agents have consistently demonstrated a positive safety and tolerability profile, and are recommended by the US National Cholesterol Education Program guidelines and by the European Joint Task Force for Prevention of Coronary Heart Disease to be used after, or in addition to, a first-line approach with diet. Several large-scale clinical trials have shown HMG-CoA reductase inhibitors to be efficacious and well tolerated, and to be associated with a low rate of treatment withdrawal due to adverse events. These studies included mortality and morbidity end-points, and comprised both primary- and secondary-prevention trials. Hepatic, renal and muscular systems are rarely affected during HMG-CoA reductase inhibitor therapy and the few drug interactions that can occur with concomitantly administered drugs are well documented. There is no conclusive evidence linking HMG-CoA reductase inhibitors to the development of cancer in humans. In long term studies with various HMG-CoA reductase inhibitors, there was no increase in cancer rates compared with placebo. Thus, it can be concluded that HMG-CoA reductase inhibitors are well tolerated, effective treatments for hypercholesterolaemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.